These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 28376677)

  • 21. Efficacy of two long-acting methylphenidate formulations in children with attention- deficit/hyperactivity disorder in a laboratory classroom setting.
    Silva R; Muniz R; Pestreich LK; Brams M; Childress A; Lopez FA
    J Child Adolesc Psychopharmacol; 2005 Aug; 15(4):637-54. PubMed ID: 16190795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.
    Weiss M; Hechtman L; Turgay A; Jain U; Quinn D; Ahmed TS; Yates T; Reiz JL; Donnelly GA; Harsanyi Z; Darke AC
    J Child Adolesc Psychopharmacol; 2007 Oct; 17(5):675-88. PubMed ID: 17979587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of methylphenidate on height and weight in Korean children and adolescents with attention-deficit/hyperactivity disorder: a retrospective chart review.
    Kim HW; Kim SO; Shon S; Lee JS; Lee HJ; Choi JH
    J Child Adolesc Psychopharmacol; 2014 Oct; 24(8):448-53. PubMed ID: 25285915
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of methylphenidate on quality of life in children with both developmental coordination disorder and ADHD.
    Flapper BC; Schoemaker MM
    Dev Med Child Neurol; 2008 Apr; 50(4):294-9. PubMed ID: 18352997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ADHD in childhood epilepsy: Clinical determinants of severity and of the response to methylphenidate.
    Rheims S; Herbillon V; Villeneuve N; Auvin S; Napuri S; Cances C; Berquin P; Castelneau P; Nguyen The Tich S; Villega F; Isnard H; Nabbout R; Gaillard S; Mercier C; Kassai B; Arzimanoglou A;
    Epilepsia; 2016 Jul; 57(7):1069-77. PubMed ID: 27237724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methylphenidate-related growth impairment.
    Holtkamp K; Peters-Wallraf B; Wüller S; Pfäaffle R; Herpertz-Dahlmann B
    J Child Adolesc Psychopharmacol; 2002; 12(1):55-61. PubMed ID: 12014596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
    Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
    Santosh PJ; Baird G; Pityaratstian N; Tavare E; Gringras P
    Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of methylphenidate on leptin and appetite in children with attention-deficit hyperactivity disorder: an open label trial.
    Işeri E; Kiliç BG; Senol S; Karabacak NI
    Methods Find Exp Clin Pharmacol; 2007; 29(1):47-52. PubMed ID: 17344944
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Attention deficit and hyperactivity disorder, methylphenidate, and epilepsy.
    Tan M; Appleton R
    Arch Dis Child; 2005 Jan; 90(1):57-9. PubMed ID: 15613514
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Attention-deficit/hyperactivity disorder with obstructive sleep apnea: a treatment outcome study.
    Huang YS; Guilleminault C; Li HY; Yang CM; Wu YY; Chen NH
    Sleep Med; 2007 Jan; 8(1):18-30. PubMed ID: 17157069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder.
    Quinn D; Wigal S; Swanson J; Hirsch S; Ottolini Y; Dariani M; Roffman M; Zeldis J; Cooper T
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1422-9. PubMed ID: 15502602
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
    Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
    Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Attention deficit/hyperactivity disorder and interictal epileptiform discharges: it is safe to use methylphenidate?
    Socanski D; Aurlien D; Herigstad A; Thomsen PH; Larsen TK
    Seizure; 2015 Feb; 25():80-3. PubMed ID: 25645642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined methylphenidate and atomoxetine pharmacotherapy in attention deficit hyperactivity disorder.
    Ozbaran B; Kose S; Yuzuguldu O; Atar B; Aydin C
    World J Biol Psychiatry; 2015; 16(8):619-24. PubMed ID: 26223958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.
    Wu EQ; Birnbaum HG; Zhang HF; Ivanova JI; Yang E; Mallet D
    J Manag Care Pharm; 2007 Sep; 13(7):561-9. PubMed ID: 17874862
    [TBL] [Abstract][Full Text] [Related]  

  • 38. OROS methylphenidate hydrochloride for adult patients with attention deficit/hyperactivity disorder.
    McBurnett K; Starr HL
    Expert Opin Pharmacother; 2011 Feb; 12(2):315-24. PubMed ID: 21226641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
    Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
    Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacological management of attention deficit hyperactivity disorder with methylphenidate and atomoxetine within a context of epilepsy].
    Mulas F; Roca P; Ros-Cervera G; Gandía-Benetó R; Ortiz-Sánchez P
    Rev Neurol; 2014 Feb; 58 Suppl 1():S43-9. PubMed ID: 25252667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.